Trial Profile
A 12-week, Prospective Study Assessing the Efficacy of Tadalafil Monotherapy and Associations between Changes in Subjective Overactive Bladder Symptoms and Changes in Oxidative Stress in Patients with Lower Urinary Tract Symptoms
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2018
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary)
- Indications Lower urinary tract symptoms; Overactive bladder
- Focus Therapeutic Use
- 28 Sep 2018 New trial record
- 31 Aug 2018 Results presented at the 48th Annual Meeting of the International Continence Society.